Chemotherapy in the elderly

Cancer Forum

Volumn 32, Issue 1, 2008, Pages 8-11

  Khasraw, Mustafa ^a   Marx, Gavin ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; KETOCONAZOLE; MACROLIDE; OXALIPLATIN; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; STEROID; TAXANE DERIVATIVE; VINCA ALKALOID;

AGING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; COGNITIVE DEFECT; COMORBIDITY; CONFERENCE PAPER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ELDERLY CARE; EMOTIONALITY; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; GLOMERULUS FILTRATION RATE; HUMAN; INFECTION; MEDICAL DECISION MAKING; NEPHROTOXICITY; NEUTROPHIL COUNT; POLYPHARMACY; SENSORY DYSFUNCTION; SIDE EFFECT; SOCIAL SUPPORT; SOLID TUMOR; TREATMENT PLANNING;

EID: 42149106775     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273-1283.
2. Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000;14:17-23.
3. Australian Bureau of Statistics. Media release 4108.1 - Older People, New South Wales, 2004; [Monograph on the internet]. Released 17/09/2004. Available from: http://www.abs.gov.au/ausstats/abs@.nsf/mediareleasesbytitle/ 425918E7B04E56CECA256F11007A8731?OpenDocument
4. Australian Bureau of Statistics. Media release 4430.0 - Disability, Ageing and Carers, Australia: Summary of Findings, 2003. [Monograph on the internet]. Released 15/09/2004. Available from: http://www.abs.gov.au/AUSSTATS/ abs@.nsf/Latestproducts/4430.0Media%20Release12003?opendocument&tabname= Summary&prodno=4430.0&issue=2003&num=&view
5. Hutchins LF, Unger JM, Crowley JJ, et al. Under-representation of patients 65 years of age or older in cancer- treatment trials. N Engl J Med. 1999;341:2061-2067.
6. Yee KW, Pater JL, Pho L, et al. Enrolment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003;21:1618-1623.
7. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer. 1994;74(suppl 7):2208-2214.
8. Talarico L, Chen G, Pazdur R. Enrolment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626-4631. Erratum in: J Clin Oncol. 2004;22:4811.
9. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2005;11: 449-460.
10. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 2005;11:461-473.
11. Duthie ED. Physiology of aging: relevance to symptom perception and treatment tolerance. In: Balducci L, Lyman GH, Ershler WB, et al, eds. Comprehensive Geriatric Oncology. 2nd ed. London; New York: Taylor & Francis; 2004.
12. Brauer PM, McKeown-Eyssen GE, Jazmaji V, et al. Familial aggregation of diabetes and hypertension in a case-control study of colorectal neoplasia. Am J Epidemiol. 2002;156:702-713.
13. Le Marchand L, Wilkens LR, Kolonel LN, et al. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res. 1997;57:4787-4794.
14. Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst. 1999;91:542-547.
15. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160-1167.
16. Wilson CJ, Cohen HJ, Pieper CF. Cross-linked fibrin degradation products (D-dimer), plasma cytokines, and cognitive decline in communitydwelling elderly persons. J Am Geriatr Soc. 2003;51:1374-1381.
17. Kishimoto T. Interleukin-6: from basic science to medicine -40 years in immunology. Annu Rev Immunol. 2005;23:1-21.
18. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47(suppl 8):C19-C31.
19. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med. 1990;6:257-267.
20. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 1997;13:169-183.
21. Kastrissios H, Blaschke TF. Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol. 1997;37:451-475.
22. Vestal RE. Ageing and pharmacology. Cancer. 1997;80:1302-1310.
23. Avorn J, Gurwitz JH. Principles of pharmacology. In Cassel CK, Cohen HJ, Larson EB, et al, Geriatric Medicine. 3rd ed. New York: Springer-Verlag; 1996.
24. Baker SD, van Schaik RH, Rivory LP, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res. 2004; 10:8341-8350.
25. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-283.
26. Schwartz JB. Race but not age affects erythromycin breath test results in older hypertensive men. J Clin Pharmacol. 2001;41:324-329.
27. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278-285.
28. Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol. 2004;38:73-77.
29. Rimon E, Kagansky N, Cojocaru L, et al. Can creatinine clearance be accurately predicted by formulae in octogenarian in-patients? QJM. 2004;97:281-287.
30. Burkhardt H, Bojarsky G, Gretz N, et al. Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimators of true glomerular filtration rate in the elderly? Gerontology. 2002;48:140-146.
31. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft- Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15:291-295.
32. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556-1564.
33. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48:133-143.
34. Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci. 2006;61:511-515.
35. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA. 2001;286:2823-2829.
36. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228-237. Erratum in: Cancer. 2004;100:1993-1994.
37. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241-252. 37.
38. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104:1998-2005.
39. Dees EC, O'Reilly S, Goodman SN, et al: A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18:521-529, 2000.
40. Lichtman SM. Physiological aspects of aging. Implications for the treatment of cancer. Drugs Aging. 1995;7:212-225.
41. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol. 1989;25:1-9.
42. Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer. 2002;38:11-16.
43. Grem JL, Takimoto CH, Multani P, et al: Antimetabolites Cancer Chemother Biol Response Modif 18:1-38, 1999.
44. Takimoto CH, Yee LK, Venzon DJ, et al: High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res 5:1347-1352, 1999
45. Raghavan D, Suh T: Cancer in the elderly population: The protection racket. J Clin Oncol 24: 1795-1796, 2006.
46. Cassidy J, Twelves C, Cameron D, et al: Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 44:453-460, 1999.
47. Wildiers H, Highley MS, de Bruijn EA, et al: Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42:1213-1242, 2003.
48. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001.
49. Folprecht G, Cunningham D, Ross P, et al:Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 15:1330-1338, 2004.
50. Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev. 2004;30:333-342.